The new approval allows for the 2000mg loading dose to be administered as an IV push rather than a 30-minute IV infusion. The prescribing information for Trogarzo ® (ibalizumab-uiyk) has been updated ...
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, ...
(RTTNews) - Theratechnologies Inc. (THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, has received FDA approval for the intravenous push mode ...
Results were announced from a phase 3 study evaluating an investigational intramuscular (IM) formulation of ibalizumab-uiyk for the treatment of heavily treatment-experienced adults with ...
Infusion therapy delivers medication through a needle or catheter and is more effective for some drugs. You may also need an infusion if you can’t take oral medication. Share on Pinterest ...
Original Medicare provides coverage for IV infusion therapy when a doctor determines it to be medically necessary, both in a clinic setting and at home. Medicare Advantage (Part C) plans need to offer ...
MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results